Clinical Trials in Japan / NCT06382987
Recruiting
Observational
A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect)
NCT06382987 · tracked via the Priya Life Science Japan tracker
Condition(s) studied
Plaque Psoriasis
Investigational drug(s) / intervention(s)
Deucravacitinib: According to the product label
Apremilast: According to the product label
Study summary
This is a prospective, observational, real-world study of adult participants in Japan with physician-reported diagnosis of plaque psoriasis treated with deucravacitinib or apremilast.
Eligibility
Inclusion Criteria:
* Japanese adult participants aged 18 years old or older
* Physician-reported diagnosis of plaque psoriasis
* Newly initiating deucravacitinib or apremilast according to the label
* Participants who have signed informed consent
Exclusion Criteria:
* Participants currently participating in or planning to participate in an interventional clinical trial
* Patients enrolled in deucravacitinib post-marketing surveillance study (ClinicalTrial.gov ID: NCT05633264)
* Previous treatment experience with the treatment of interest (e.g. patients who have history of apremilast will not be eligible to be enrolled in apremilast arm of the study and similar for deucravacitinib)
Primary outcome measure(s)
- Change in percent Body Surface Area (BSA) involved affected by plaque psoriasis from baseline to follow up in participants treated with deucravacitinib. — 1 month, 3 months, 6 months and every 6 months up to 5 years
- Number of participants who achieved Physician's Global Assessment (PGA) of 0/1 from baseline to follow-up — 1 month, 3 months, 6 months and every 6 months up to 5 years
- Number of participants who achieved Absolute Psoriasis Area and Severity Index (aPASI) of ≤2 from baseline to follow-up — 1 month, 3 months, 6 months and every 6 months up to 5 years
- Number of participants who achieved Dermatology Life Quality Index (DLQI) of 0 /1 from baseline to follow-up — 1 month, 3 months, 6 months and every 6 months up to 5 years
- Participant duration of treatment (time difference between date of treatment initiation to date of discontinuation) — 1 month, 3 months, 6 months and every 6 months up to 5 years
Trial sites (2)
| Facility | City | Region | Status |
|---|---|---|---|
| Mebix. Inc. | Minato-ku | Tokyo | Recruiting |
| Fukuoka University Hospital | Fukuoka | Japan | Recruiting |
On this site
📄 Otezla (apremilast) drug profile →More Bristol-Myers Squibb trials in Japan
Other trials for the same condition
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
Active, not recruiting
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
Active, not recruiting
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06382987 on ClinicalTrials.gov ↗ ← All trials in Japan